Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Healthy Yuan (600380.SH): Key data obtained in Phase III clinical trial of sequential booster immunization with recombinant COVID-19 fusion protein vaccine of Lizhu.

Published Time:

2022-02-17

GELONGHUI February 16 | Jiankangyuan (600380.SH) announced that its subsidiary, Lizhu Pharmaceutical Group Co., Ltd.'s subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd. (referred to as "Lizhu Monoclonal Antibody"), has completed the interim primary data analysis of the Phase III clinical trial of its "recombinant novel coronavirus fusion protein vaccine" and obtained key data.

 

This sequential booster regimen is designed as a sequential booster based on two doses of inactivated vaccine, using a relatively strong and superior protection standard, which is different from the traditional blank placebo regimen. V-01 conducted Phase III clinical trials of sequential boosting in Pakistan and Malaysia, planning to inject V-01 booster or blank placebo in a 1:1 ratio among a total of 10,722 healthy adults aged 18 and above who completed 2 doses of inactivated vaccine 3-6 months ago.

 

As of the date of this key data analysis, 10,241 people were actually enrolled, and a total of 110 cases of primary endpoint events were monitored after vaccination (the protocol requires analysis when at least 103 primary endpoint cases are available). According to the results of the current stage analysis: Compared with two doses of inactivated vaccine, the annual incidence rate of the V-01 sequential booster group and the two-dose inactivated vaccine group were 6.73% and 12.80%, respectively, with a significant difference (P=0.0012); the absolute protective efficacy of V-01 sequential booster was 61.35%, with significantly superior efficacy. The absolute protective efficacy of V-01 sequential booster has met the WHO standard. The genotyping sequencing of 60 of all the effectively tested samples in this trial was Omicron (the rest are still undergoing second-generation sequencing), indicating that V-01 sequential booster can produce good protection against COVID-19 caused by Omicron infection. At the same time, no safety concerns of note were found.

 

According to the LSHTM tracker, as of February 7, 2022, there were 121 COVID-19 vaccine products in clinical trials worldwide, of which 27 have been approved for marketing or emergency use. In China, 4 have received conditional approval (no recombinant protein technology route products), 7 have received emergency use approval (including 1 recombinant protein technology route product), and a total of 21 are in clinical trials (8 recombinant protein technology route products).

 

To date, Lizhu Monoclonal Antibody has accumulated approximately RMB 509 million in direct R&D investment in the V-01 project (including I/II phase clinical trials, sequential boosting and basic immunization III phase clinical trials).

 

From: GELONGHUI